Physician

Charles Wade Taylor, M.D.

According to 2025 Medicare claims, Charles Taylor, M.D. (NPI: 1003859679) practices medical oncology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (NPI: 1962876045; TIN: 383983999) and primary practice location at 74146-6236.

Taylor's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,276 traditional Medicare patients, billed 188,620 HCPCS/CPT codes, and received $3,046,251 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,323 prescription claims across 372 beneficiaries totaling $6,384,226 in drug costs, led by Ibrance (Palbociclib). DME data shows 127 claims. Open Payments data shows 20 records totaling $34,807. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,510,676 to $3,046,251. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,668,346 to $6,384,226. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,681 to $1,075.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,041	169,851	$1,510,676
2016	1,131	95,882	$1,390,468
2017	1,063	81,396	$1,241,678
2018	1,159	99,437	$1,687,969
2019	1,149	88,539	$1,790,029
2020	1,458	160,120	$3,096,659
2021	1,637	227,784	$3,984,466
2022	1,423	208,075	$3,264,675
2023	1,369	223,893	$3,671,325
2024	1,276	188,620	$3,046,251

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	242	1,410	$1,668,346
2016	345	2,142	$2,703,093
2017	384	2,720	$3,803,528
2018	391	2,693	$3,430,097
2019	397	2,616	$3,947,841
2020	398	2,790	$4,987,810
2021	415	2,496	$5,452,524
2022	392	2,524	$5,719,986
2023	364	2,297	$5,966,530
2024	372	2,323	$6,384,226

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	22	128	$40,498
2016	11	87	$20,474
2017	N/R	83	$20,936
2018	N/R	102	$12,570
2019	N/R	34	$3,775
2020	N/R	28	$1,278
2021	N/R	100	$6,552
2022	N/R	79	$3,225
2023	N/R	84	$26,429
2024	11	127	$4,761

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	509	966	$85
80053	Blood test, comprehensive group of blood chemicals	501	1,407	$10
36415	Insertion of needle into vein for collection of blood sample	572	1,441	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	512	1,483	$8
84550	Uric acid level, blood	418	1,269	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	74	2,072	$913,084
Revlimid	Lenalidomide	55	1,358	$852,081
Venclexta	Venetoclax	42	1,252	$605,254
Imbruvica	Ibrutinib	31	876	$485,780
Alecensa	Alectinib Hcl	20	600	$370,045

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	11	14	$1,291
J8521	Capecitabine, oral, 500 mg	N	N/R	31	$1,252
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$881
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	25	$471
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	12	$421

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$195	Ipsen Biopharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	11	$34,612	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Wade Taylor, M.D.?

Tedicare shows public-source Medicare data for Charles Wade Taylor, M.D. (NPI 1003859679), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Wade Taylor, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Charles Wade Taylor, M.D.?

Charles Wade Taylor, M.D. is linked to OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (billing NPI 1962876045) in the available physician profile data.

Does Charles Wade Taylor, M.D. have Open Payments data?

Charles Wade Taylor, M.D. has 20 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.